Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA ‐matched unrelated donor HCT in paediatric acute leukaemia
British Journal of Haematology · 2024-05 · 204 (5) · 1935-1943
DOI: 10.1111/bjh.19356 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 05.03.2024. Verfasst von Elizabeth Krieger und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Receptors, KIR, Unrelated Donors, Graft vs Host Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Killer immunoglobulin‐like receptor (KIR) and KIR‐ligand (KIRL) interactions play an important role in natural killer cell‐mediated effects after haematopoietic stem cell transplantation (HCT). Previous work has shown that accounting for known KIR–KIRL interactions may identify donors with optimal NK cell‐mediated alloreactivity in the adult transplant setting. Paediatric acute leukaemia patients were retrospectively analysed, and KIR‐KIRL combinations and maximal inhibitory KIR ligand (IM‐KIR) scores were determined. Clinical outcomes were examined using a series of graphs depicting clinical events and endpoints. The graph methodology demonstrated that prognostic variables significant in the occurrence of specific clinical endpoints remained significant for relevant downstream events. KIR‐KIRL combinations were significantly predictive for reduced grade 3–4 aGVHD likelihood, in patients transplanted with increased inhibitory KIR gene content and IM‐KIR = 5 scores. Improvements were also observed in associated outcomes for both ALL and AML patients, including relapse‐free survival, GRFS and overall survival. This study demonstrates that NK cell KIR HLA interactions may be relevant to the paediatric acute leukaemia transplant setting. Reduction in aGVHD suggests KIR effects may extend beyond NK cells. Moving forward clinical trials utilizing donors with a higher iKIR should be considered for URD HCT in paediatric recipients with acute leukaemia to optimize clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Virginia Commonwealth University, Richmond, Virginia, USA.
- Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA.
- Lehigh Valley Health Network, Allentown, Pennsylvania, USA.
- Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
ORCID-Profile: Rehan Qayyum, Amir Toor
Förderung
- NIEHS NIH HHS
- NCI NIH HHS
Zitieren
APA
Krieger, E., Qayyum, R., & Toor, A. (2024). Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA ‐matched unrelated donor HCT in paediatric acute leukaemia. British Journal of Haematology, 204(5), 1935-1943. https://doi.org/10.1111/bjh.19356
Vancouver
Krieger E, Qayyum R, Toor A. Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA ‐matched unrelated donor HCT in paediatric acute leukaemia. British Journal of Haematology. 2024;204(5):1935-1943. doi:10.1111/bjh.19356
BibTeX
@article{Krieger2024,
author = {Krieger, Elizabeth and Qayyum, Rehan and Toor, Amir},
title = {Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA ‐matched unrelated donor HCT in paediatric acute leukaemia},
journal = {British Journal of Haematology},
year = {2024},
volume = {204},
number = {5},
pages = {1935--1943},
doi = {10.1111/bjh.19356}
}
EUVIMED